2007 archivos - Histopat laboratoris

A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer

Sanchez-Carbayo M, Socci ND, Kirchoff T, Erill N, Offit K, Bochner BH and Cordon-Cardo C.

Division of Molecular Pathology, Computational Biology Center, and Departments of Medicine and Urology, Memorial Sloan-Kettering Cancer Center, New York, New York; Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; and BIOPAT, Grup Assistencia, Barcelona, Spain

Abstract

Purpose: The HDM2 gene represents one of the central nodes in the p53 pathway. A recent study reported the association of a single nucleotide polymorphism (SNP309) in the HDM2 promoter region with accelerated […]

Alberto 2007-06-01T12:48:34+00:00

Topoisomerase II-Alpha gene copy number alterations in ERBB2-Positive primary breast carcinomas: A fluorescence in situ hybridization study

A Colomer¹, N Erill¹, M Górriz^1,2, M Verdú², R Roman¹, R Ibáñez¹, C Cordon-Cardo¹ and X Puig^1,2.

^{1BIOPAT. Biopatologia Molecular, SL, Grup Assistència, Barcelona, Spain and 2 Histopat Laboratoris, Barcelona, Spain.}

Background: Topoisomerase II-alpha gene (TOP2A) aberrations have been recently pointed as predictive markers of anthracycline-based adjuvant chemotherapy in breast cancer. While coamplification of ERBB2 and TOP2A seems to define a subgroup of high-risk patients likely to benefit from anthracycline treatment, the significance of a patient having TOP2A deletions in […]

Alberto 2007-03-23T17:36:46+00:00